Hutter, J. N., Robben, P. M., Lee, C., Hamer, M., Moon, J. E., Merino, K., Zhu, L., Galli, H., Quinn, X., Brown, D. R., Duncan, E., Bolton, J., Zou, X., Angov, E., Lanar, D. E., Rao, M., Matyas, G. R., Beck, Z., Bergmann-Leitner, E., Soisson, L. A., Waters, N. C., Ngauy, V., Regules, J., & Dutta, S. (2022). first-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults. Vaccine, 40(40), 5781–5790. http://access.bl.uk/ark:/81055/vdc_100164964452.0x000041